SOURCE: NanoViricides, Inc.

NanoViricides, Inc.

December 18, 2013 09:27 ET

NanoViricides CEO Dr. Eugene Seymour to Be Interviewed on Clear Channel DFW 1190AM

Eugene Seymour to Be Interviewed Live Dec 19th on Traders Financial Network Radio Show by Host Michael Yorba

WEST HAVEN, CT--(Marketwired - Dec 18, 2013) - NanoViricides, Inc. (NYSE MKT: NNVC) is a development stage company that is creating special purpose nanomaterials to destroy viruses in and on the body. The Company announced today that CEO Dr. Eugene Seymour will be interviewed live by Michal Yorba on Clear Channel Business Talk Radio's Traders Financial Network, Thursday, December 19th, 2013, at 2:00pm CST / 12:00pm PST / 3:00pm EST.

DETAILS
Live Interview via iHeart Radio Stream:
http://www.iheart.com/live/4276/?autoplay=true
Date: December 19th 2013
Time: 2:00pm CST | 12:00pm PST | 3:00pm EST
Network: Clear Channel
Station: DFW 1190AM
Host: Michael Yorba

About Clear Channel Clear Channel Media and Entertainment's more than 840 radio stations offer programming nationwide. Individual station brands connect with diverse audiences in local markets across the country. DFW1190AM.com Dallas-Ft. Worth, TX www.clearchannel.com

About Michael Yorba Michael Yorba -- featured host of Clear Channels DFW 1190AM in Dallas-Ft.Worth. For the past six years he has been integrally involved with the media industry in various capacities including building an IPTV Network, developing, producing and hosting a daily one hour talk show called Commodity Classics and then later The Traders Network, defined as an audience empowered interactive financial program that has been broadcast live on internet television and radio. His focus has been on derivative portfolio analysis for individual and corporate clients through the use of futures and futures options, managed funds, and Forex. www.yorbamedia.com.

About NanoViricides

NanoViricides, Inc. (www.nanoviricides.com ) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

A www.1800PublicRelations.com PR Event

Contact Information